Search Results - "Starr, Jason Scott"

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer by Chakrabarti, Sakti, Bucheit, Leslie, Starr, Jason Scott, Innis-Shelton, Racquel, Shergill, Ardaman, Dada, Hiba, Resta, Regina, Wagner, Stephanie, Fei, Naomi, Kasi, Pashtoon Murtaza

“…Clinical trials reporting the robust antitumor activity of immune checkpoint inhibitors (ICIs) in microsatellite instability-high (MSI-H) solid tumors have…”
Get full text

Circulating tumor DNA analysis of neuroendocrine tumors by Starr, Jason Scott, Mody, Kabir, Roberts, Ali, Kasi, Pashtoon Murtaza

“…Abstract only e15698 Background: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a diverse group of tumors with an equally diverse biology and clinical…”
Get full text

Factors affecting time to treatment in hepatocellular cancer by Seegobin, Karan, Majeed, Umair, Ritter, Ashton, Wylie, Natasha, Starr, Jason Scott, Jones, Jeremy Clifton, Mody, Kabir

“…Abstract only e19088 Background: Significant disparities in the stage at diagnosis and survival outcomes exist between various groups diagnosed with…”
Get full text

Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis by Sonbol, Mohamad Bassam, Mazza, Gina L., Starr, Jason Scott, Hobday, Timothy J., Halfdanarson, Thorvardur Ragnar

“…Abstract only 629 Background: Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms with outcome varying by stage, grade, and clinical presentation. We…”
Get full text

Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer by Kamatham, Saivaishnavi, Colibaseanu, Dorin, Merchea, Amit, Shahjehan, Faisal, Starr, Jason Scott, Mody, Kabir, Kasi, Pashtoon Murtaza

“…Abstract only e15066 Background: Circulating cell-free tumor-DNA (ctDNA) testing (‘liquid biopsy’) is increasingly being employed both in clinical trials as…”
Get full text

Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients by Kasi, Pashtoon Murtaza, Kamatham, Saivaishnavi, Colibaseanu, Dorin, Merchea, Amit, Shahjehan, Faisal, Starr, Jason Scott, Mody, Kabir

“…Abstract only 3566 Background: According to the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint review on…”
Get full text

Systematic analysis of extracting data on advance directives from patient electronic health records in terminal oncology patients by Skelton, William Paul, Starr, Jason Scott, Rahmanian, Kiarash, Guenther, Robert, Allen, William L., George, Thomas J., Moseley, Ray E.

“…Abstract only e24011 Background: Advanced care planning and living wills are critical components of caring for patients at the end of their lives. Advance…”
Get full text

Quality Improvement: Decreasing Length of Stay and Readmission Rates for Bone Marrow Transplant Patients by Starr, Jason Scott, D.O, Mobley, Erin, MPH, Roy, Vivek, M.D, Wade, John, RN, Lesperance, Virginia, RN

Get full text

Clinical significance of brain metastases in patients with bronchopulmonary neuroendocrine tumors: A population-based analysis by Fuentes, Harry E, Zhu, Mojun, Gile, Jennifer, Leventakos, Konstantinos, Sonbol, Mohamad Bassam, Schild, Steven E., Starr, Jason Scott, Halfdanarson, Thorvardur Ragnar, Molina, Julian R.

“…Abstract only e21575 Background: The clinical significance of brain metastases in patients with bronchopulmonary neuroendocrine (NE) tumors is unknown; we…”
Get full text

Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs) by McGarrah, Patrick Walsh, Hobday, Timothy J., Starr, Jason Scott, Kendi, Ayse T., Graham, Rondell P., Sonbol, Mohamad Bassam, Halfdanarson, Thorvardur Ragnar

“…Abstract only 617 Background: Currently, there is no published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have…”
Get full text

Central venous access in oncology patients: A pragmatic approach to minimizing complications following port insertion by Skelton, William Paul, Franke, Aaron J, Woody, Lindsey, Welniak, Samantha, Bosse, Raphael, Murphy, Martina Cathryn, Starr, Jason Scott

“…Abstract only 267 Background: Subcutaneous venous access devices, specifically implantable ports, are vital in the care of oncology patients. Despite routine…”
Get full text

Retrospective analysis of complications following central venous port insertions: A single institution experience by Skelton, William Paul, Franke, Aaron J, Welniak, Samantha, Bosse, Raphael, Ayoub, Fares, Murphy, Martina Cathryn, Starr, Jason Scott

“…Abstract only…”
Get full text

Blood-based next-generation sequencing analysis of neuroendocrine tumors by Shaib, Walid Labib, Roberts, Ali, Zakka, Katerina Mary, Akce, Mehmet, Wu, Christina, Alese, Olatunji B., El-Rayes, Bassel F., Kasi, Pashtoon Murtaza, Starr, Jason Scott

“…Abstract only 4110 Background: Neuroendocrine tumors (NET) comprise around 2% of all malignant tumors of the gastrointestinal system. The genomic landscape of…”
Get full text

Impact of obesity upon the survival of cholangiocarcinoma patients by Surapaneni, Phani Keerthi, Li, Zhuo, Vemireddy, Lalitha Padmanabha, Kasi, Pashtoon Murtaza, Starr, Jason Scott, Ritter, Ashton, McMillan, Jessica, Wylie, Natasha, Mody, Kabir

“…Abstract only 288 Background: Obesity is a risk factor for developing cholangiocarcinoma (CCA). However, the effect of obesity on survival of CCA is unclear…”
Get full text

Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA) by Kankeu Fonkoua, Lionel Aurelien, Chakrabarti, Sakti, Sonbol, Mohamad Bassam, Kasi, Pashtoon Murtaza, Starr, Jason Scott, Liu, Alex J, Bois, Melanie C., Pitot, Henry C., Ross, Helen J., Wu, Tsung-Teh, Graham, Rondell P., Markovic, Svetomir, Dong, Haidong, Yoon, Harry H.

“…Abstract only 362 Background: Most pts with mGEA do not respond to ICI or ramucirumab/paclitaxel (RAM/TAX). Emerging data suggest that ICI may potentiate…”
Get full text

Results from an institutional universal reflex testing program for MSI/MMR in colorectal cancer by Franke, Aaron J, Gaffar, Maira, Feely, Michael, Starr, Jason Scott, Parekh, Hiral D., Tan, Sanda, Iqbal, Atif, Allegra, Carmen Joseph, George, Thomas J.

“…Abstract only 796 Background: In colorectal cancer (CRC), clinical guidelines and immunotherapy treatment selection requires knowledge of tumor DNA mismatch…”
Get full text

Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC) by Mody, Kabir, Kasi, Pashtoon Murtaza, Surapaneni, Phani Keerthi, Borad, Mitesh J., Ahn, Daniel H., Mahipal, Amit, Starr, Jason Scott, Ritter, Ashton, McMillan, Jessica, Wylie, Natasha, Roberts, Ali, Nagy, Rebecca J, Bekaii-Saab, Tanios S.

“…Abstract only 289 Background: PDAC has limited treatment options. Genomic analyses have led to development of targeted therapies now in several clinical…”
Get full text

Landscape of circulating tumor DNA and tissue-based profiling in advanced cholangiocarcinoma by Mody, Kabir, Kasi, Pashtoon Murtaza, Surapaneni, Phani Keerthi, Bekaii-Saab, Tanios S., Ramanathan, Ramesh K., Ahn, Daniel H., Mahipal, Amit, Starr, Jason Scott, Ritter, Ashton, McMillan, Jessica, Wylie, Natasha, Roberts, Ali, Nagy, Rebecca J, Borad, Mitesh J.

“…Abstract only 291 Background: Cholangiocarcinoma (CCA) has limited treatment options. Genomic analyses have led to development of targeted therapies now in…”
Get full text

Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia) by Kasi, Pashtoon Murtaza, Dayyani, Farshid, Morris, Van K., Kopetz, Scott, Parikh, Aparna Raj, Starr, Jason Scott, Cohen, Stacey, Grothey, Axel, Lieu, Christopher Hanyoung, O'Hara, Mark H., Loranger, Kate, Westbrook, Laura, Sharma, Shruti, Krinshpun, Shifra, Hook, Nicole, Zimmermann, Bernhard, Billings, Paul R., Aleshin, Alexey

“…Abstract only 4108 Background: Circulating tumor DNA (ctDNA) testing can be used for the assessment of molecular residual disease (MRD) in patients with…”
Get full text

Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA) by Kankeu Fonkoua, Lionel Aurelien, Chakrabarti, Sakti, Sonbol, Mohamad Bassam, Kasi, Pashtoon Murtaza, Starr, Jason Scott, Liu, Alex John, Bois, Melanie C., Pitot, Henry C., Chandrasekharan, Chandrikha, Ross, Helen J., Wu, Tsung-Teh, Graham, Rondell P., Markovic, Svetomir, Dong, Haidong, Yoon, Harry H.

“…Abstract only 4541 Background: Anti-VEGFR2 therapy (ramucirumab/paclitaxel [RAM/TAX]) and ICI are approved as 2 nd - and 3 rd -line therapy (Tx), respectively,…”
Get full text